No Data
Candel Therapeutics | 10-Q: Quarterly report
Express News | Candel Therapeutics Inc: Qtrly Shr Loss $0.28
Express News | Candel Therapeutics: Expects Existing Cash and Cash Equivalents Will Be Sufficient to Fund Its Current Operating Plan Into Q4
Candel Therapeutics 1Q Research and Development Expenses $4.1M >CADL
Candel Therapeutics 1Q Research and Development Expenses $4.1M >CADL
Express News | Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Express News | Candel Therapeutics Q1 Net Income USD -8.221 Million
70959052OP : This will be legenadry 10x easy from here